The role of brevican in glioma: promoting tumor cell motility in vitro and in vivo
© Lu et al.; licensee BioMed Central Ltd. 2012
Received: 9 October 2012
Accepted: 11 December 2012
Published: 19 December 2012
Malignant glioma is a common primary tumor of the central nervous system. Brevican, an abundant extracellular matrix component in the adult brain, plays a critical role in the process of glioma. The mechanisms for the highly invasive behavior of gliomas are still poorly understood. The aim of this study was to examine whether brevican is a predictor of glioma and its roles in glioma cell motility.
In this study, immunohistochemistry staining for brevican expression was performed in malignant gliomas and benign controls. We also explored the effects of brevican on cell adhesion and migration in brevican-overexpressed cells. Knockdown of brevican expression was achieved by stable transfection of U251 cells transduced with a construct encoding a short hairpin DNA directed against the brevican gene, which correspondingly, down-regulated the proliferation, invasion and spread of brevican-expressing cells. Moreover, the role of brevican in the growth and progression of glioma was demonstrated by in vivo studies.
Our results provide evidence for the molecular and cellular mechanisms that may underlie the motility-promoting role of brevican in the progression of glioma. The role of brevican as a target for immunotherapy might be taken into consideration in future studies.
This study suggests that expression of brevican is associated with glioma cell adhesion, motility and tumor growth, and also is related to glioma cell differentiation, therefore it may be a marker for malignance degree of glioma
KeywordsBrevican Glioma Astrocytoma Motility Tumorigenicity
Malignant glioma, the most common primary tumor in the central nervous system (CNS) with an almost invariably rapid and lethal outcome, is characterized by a distinctive ability to invade the surrounding tissue . Tumor cell invasion is a particular problem at the time of recurrence after the failure of anti-angiogenesis treatment, resulting in neurological deficits and eventual patient demise [2, 3]. Yet, at this time, no drug treatment is available that can interfere with the invasiveness of malignant gliomas.
Brevican is one of the most abundant proteoglycans (PGs) in the postnatal brain and is the smallest core protein among the lectican family [4–6]; its gene is located on chromosome 1q31 and includes 14 exons . Recent studies have shown that brevican expression is restricted within the CNS, including the brain and spinal cord, but is absent in extracranial organs, such as the heart, muscle, liver, kidney, lung, thymus and spleen . Interesting, malignant gliomas exhibit unique brevican isoforms, and brevican is critical for its proinvasive role in glioma .
Brevican expression is induced in intracranial grafts of invasive glioma cell lines . Evidence has shown that the coding sequence of the brevican gene in glioma is the same as the brevican gene found in the cortex of the normal brain. Therefore, the regulation of expression of brevican in glioma is not caused by mutation . To date, our understanding of the regulatory mechanisms of brevican functions and the involvement of PGs in cancer is limited. In our previous mass spectrometry screening in the cerebrospinal fluid (CSF), we found brevican was overexpressed in glioma patients. In this paper, the implication of brevican in cancer development and progression is discussed. Our results demonstrated a motogenic role for brevican and suggested that brevican was a key enhancing factor in the progression of glioma. Targeting brevican might offer a novel and promising approach to cancer immunotherapy by engaging the tumor microenvironment.
Tumor tissues of glioma and the control group
The characteristics of 60 patients with malignant glioma
Number of patients (N = 60; %)
Degree of differentiation
Well (hair cell type-, oligodendrocyte type- astrocytoma)
Poorly (anaplastic astrocytoma, glioblastoma)
The human glioma U251MG and U87 cell lines, and the non-glioma cell line 293T were obtained from the American Type Culture Collection (Manassas, VA). The cells were grown in DMEM medium (Invitrogen, Grand Island, NY) supplemented with 10% fetal bovine serum, 50 units/mL penicillin, and 50 μg/mL streptomycin in a humidified atmosphere with 5% CO2 at 37°C.
Construction of recombinant plasmids and production of anti-brevican antibodies
The pIRES-hrGFP-brevican plasmid containing the full sequence of brevican was provided by a Department of Neurology laboratory at the Beth Israel Deaconess Medical Center. The brevican fragment was subcloned into the pMX-puro(+) vector (Invitrogen) to yield pMX-brevican, which was then transfected into 293T, U251 and U87 cells using Fusion 6® (Roche, Mannheim, Germany). In addition, the DNA sequence for the N-terminal domain (aa 22–104) of brevican was amplified using the primers 5’-ACGGATCCGCAGATGTTCTGGAAGGAGACA-3’ (P1) and 5’-CCGCTCGAGGTAGGCCTCGTTCACCTTGAC- 3’ (P2). The brevican N-terminus was also subcloned into the PGEX-4T-1 expression vector (Invitrogen), and brevican recombinant protein was obtained successfully. The anti-brevican antibody B5 was obtained using immunized New Zealand rabbits, performed as previously described .
Immunohistochemical (IHC) staining
The paraffin sections were dewaxed and hydrated, followed by antigen repairing for 20 min. Rabbit anti-brevican antibody (B5) was then added at 4°C overnight, and horseradish peroxidase labeled anti-rabbit IgG at 37°C was incubated for 1 h. Then 0.05% DAB was added for 5 min, hematoxylin for 1 min, and eosin for 2 min. The IHC sections were stained by hematoxylin and eosin (HE), and scanned under microscopy. The positive index (PI) was calculated using the following formulation: PI = i × p, where i is intensity of staining (0 for negative, blue; 1 for weakly-positive, light yellow; 2 for medium positive, yellow; 3 for strong positive, brown), and p is positive percentage of staining (1 for ≤10%; 2 for 11%-50%; 3 for 51%-75%; 4 for >75%) . The PI of glioma specimens was compared with that of the control tumors.
Knockdown of brevican expression was achieved using recombinant plasmids containing short hairpin DNA (shDNA), which were constructed by cloning the respective shDNA into the pSuper-puro vector (Invitrogen). The candidate sequences of the shDNAs were as follows: shDNA 1, 5’GATCCCCGGTGAACGAGGCCTACCGGTTCAAGAGACCGGTAGGCCTC GTTCACCTTTTTGGAAA3’, shDNA 2, 5’GATCCCCGTTATGCTGAAGACCTAAATTC AAGAGATTTAGGTCTTCAGCATAACTTTTTGGAAA3’, shDNA 3, 5’GATCCCCGGAG GAAGAAGAGAAATATTTCAAGAGAATATTTCTCTTCTTCCTCCTTTTTGGAAA3’. A mock plasmid was constructed using the scrambled shDNA sequence 5’-GATCCCCGCTCCTAGAATTTGAAACATTCAAGAGATGTTTCAAATTCTAGGAGCTTTTTGGAAA-3’. Stably transduced U251 cells that overexpress brevican were transfected with these plasmids for 24 h and then treated with 1.0 μg/mL puromycin. The remaining cells were cultured with 0.5 μg/mL puromycin until cell colonies formed, and Western blots were used to test for brevican levels.
Cell adhesion and migration assays
The stably transduced cells were resuspended in culture medium. A total of 50,000 suspended cells were added to a 96-well plate coated with human fibronectin (20 μg/mL; Solarbio, Beijing) and poly-L-lysine (50 μg/mL; Sigma, St. Louis, MO). After an 1 h incubation, the plates were washed with PBS, fixed with 4% paraformaldehyde, and the 570 nm absorbance was quantified after crystal violet staining. For the migration assay, cells diluted in serum-free culture medium were plated onto 24-well plates preloaded with Transwell inserts (8 μm pore size; Costar, Cambridge, MA) at 50,000 cells per well in 100 μl culture medium and allowed to migrate for 10 h. Subsequently, the cells that had migrated to the underside were stained and counted using microscopy. All experiments were repeated at least three times.
Cell proliferation, invasion and wound healing assays
The transduced cells were plated on 24-well plates (1000 cells/well) and the cell colonies were counted at day 12 to measure the cell proliferation rate. For cell invasion experiments, Matrigel was plated inside Transwell culture inserts for 5 h at 37°C before cells were plated onto the inserts (50,000 cells/well). After 16 h, the cells that migrated to the underside were stained and counted.
For the cell wound healing assays, a cell scraper was used to create scratch wound on a dish with cells grown to 80% confluence. The distances of the wounds were then measured using a microscope at 0, 24 and 48 h. Cell motility was evaluated using the following formula: cell motility = (distance24h or 48h – distance0h)/ distance0h.
Cells were grown on a slide chamber for 24 h, fixed for 10 min in a cold mixture of methanol and acetone, and blocked with PBST containing 0.5% bovine serum albumin for 2 h. Cells were incubated with anti-brevican polyclonal antibody B5 (1: 100) overnight at 4°C, followed by incubation with CFTM 488A labeled goat anti-rabbit secondary antibodies (Biotium, Hayward, CA) for 30 min at 37°C. The cells were then observed under fluorescence microscopy.
Whole cell lysates were used for immunoblotting as described previously . Enhanced chemiluminescence detection was performed according to the manufacturer’s instructions with an ECL kit (Thermo Scientific, Rockford, IL).
To validate the effects observed with brevican knockdown in vitro, BALB/c nude mice were injected subcutaneously into the right flank with either the 5×106 U251 transduced cells, transduced U251/brevican-shDNA mock, or transduced U251/ brevican-shDNA 2. BALB/c nude mice (five mice per group) were purchased from the National Rodent Laboratory Animal Resources (Shanghai). Tumor measurements were made every 4 days and tumor sizes were calculated using the formula V= 0.5a’ × b’2, where a’ and b’ were the long and short diameters of the tumor. In addition, 2×105 cells were intracranially injected into the right thalamus of BALB/c nude mice using a 10 μl syringe. A total volume of 8 μl cell suspension was injected at 2.5 mm anterior to the bregma and 2.0 mm lateral to the midline into three mice for each group. Magnetic resonance tomography (MRT) was used for comparing the orthotopic tumor growth in the nude mice.
A one-way ANOVA was performed using SPSS 13.0 software (SPSS Inc., Chicago, IL). The results were expressed as the means ± SD, and a P value < 0.05 was considered to be statistically significant.
Brevican is differentially expressed in glioma and benign brain tumors
Brevican expression and the clinicopathological characteristics of 60 patients with malignant glioma.
positive cases (%)
negative cases (%)
Degree of differentiation
Brevican overexpression promoted cell adhesion and migration
Knockdown of brevican gene inhibited cell motility abilities
Brevican knockdown inhibits tumorigenicity in vivo
The ECM has an active role in regulating the activity and behavior of cells, including cell shape, differentiation, proliferation and cell death. In recent studies, the nervous ECM (NECM) was re-evaluated. To date, several studies showed that the solubility of the NECM increased in glioma, which might be related to the up-regulation of brevican [18–21].
In this study, we first explored the physiological role of brevican by investigating its spatiotemporal expression by IHC. Brevican was abundantly expressed in glioma tissues, particularly in grade III and grade IV astrocytomas, whereas brevican only expressed weakly in pituitary adenoma tumor tissue and negative in meningioma tissue. These data suggest that brevican is produced by astrocytoma cells, before being secreted and bound to the cellular cytoplasm and ECM. In the transduced brevican-expressing U251 cells, brevican was also detected on the surface of these cells using cytoimmunofluorescence. The expression of a tumor-specific brevican found in all high-grade gliomas suggested that it might play a significant role in glioma progression. Moreover, previous studies have shown that brevican is expressed at relatively low levels in normal adult brain [10, 22]. Therefore, the absence or down-regulation of brevican in benign gliomas prompts its use as a differentiation marker to distinguish primary brain tumors with similar histology, but with a different pathologic course.
Here, we established an in vitro model to reproduce the motogenic effects of brevican. Our results indicated that brevican can promote cell adhesion and was essential for the migration of U251 cells. Brevican may interact with fibronectin (FN) to act as a motogenic signal. FN interacts with multiple cell surface receptors and plays an important role in the regulation of anchorage-dependent cell growth, cell migration, tumor development and metastasis. Cell adhesion to immobilized FN leads to the assembly of focal adhesions, which require the small GTPase Rho and then affect many cellular functions, such as cell motility, differentiation, matrix assembly, and cell cycle progression . A combination of brevican cytological mechanisms and the particular composition of the neural microenvironment may underlie this unique ability of glioma to disperse in the CNS. In addition, it has been demonstrated that secreted brevican isoforms have evolved to become the predominant brevicans in the adult brain . Our studies suggested that brevican overexpression in glioma is associated with cancer progression, and therefore, brevican might be a useful biomarker of glioma.
Furthermore, we also generated brevican knockdown transduced U251 cells using loss-of function techniques. We found that brevican knockdown affected cell invasion and might explain how endogenous brevican exerts its effects on cell adhesion. We confirmed that brevican can promote glioma cell adhesion [15, 25]. Moreover, a distinct inhibition of the spreading and expression of brevican was observed surrounding the core of suppressed transduced U251 cells using a cytoimmunofluorescence assay. At this point we speculate that mechanisms that recycle adhesion receptors via endosomal compartments may contribute to migration. Results from our wound-healing experiments confirm this hypothesis.
Gliomas are highly invasive . The ability of tumor cells to interact with the components of the NECM affects numerous cellular processes, and inappropriate expression of these matrix components has been associated with glioma invasion and growth [8, 14]. One NECM component that has been implicated in glioma biology is brevican, and increasing studies have focused on brevican and mechanisms of glioma invasion in recent years . Brevican’s involvement in glioma invasion may explain why many physiological processes require closely regulated degradation of the NECM .
In light of the effects of brevican on cell motility, we investigated the tumorigenicity of differential brevican expression in vivo. To date, little is known of the molecular basis that allows glioma cells to overcome the barriers that inhibit motility in the adult nervous tissue [29–31]. In this study, we found that brevican was highly overexpressed in glioma and distinctively promoted cell adhesion ability. The change of the NECM in the nervous system is critical for tumor cell aggression and invasion. To overcome the barriers to cell motility, glioma cells degrade the NECM and secrete their own matrix components. Our work demonstrated that the xenograft transplants using brevican knockdown cells gave rise to much smaller tumors, and had less diffuse and less infiltrative tumors than those of control groups. Overall, the deposition of brevican into the NECM may disrupt matrix processing and alter extracellular molecular events that modulate neural solubility.
This study indicates that the expression of brevican is associated with glioma cell adhesion, motility and tumor growth. Brevican also plays an important role in glioma progression, and therefore, may be a useful marker of glioma.
Central nervous system
Hematoxylin and eosin
Short hairpin DNA
Nervous extracellular matrix.
This work was supported by grants from the National Natural Science Foundation of China (project number: 30870565 and 81171912).
- Bolteus AJ, Berens ME, Pilkington GJ: Migration and invasion in brain neoplasms. Curr Neurol Neurosci Rep. 2001, 1 (3): 225-232. 10.1007/s11910-001-0022-x.View ArticlePubMed
- Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, et al: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008, 70 (10): 779-787. 10.1212/01.wnl.0000304121.57857.38.View ArticlePubMed
- Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB: Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 2009, 73 (15): 1200-1206. 10.1212/WNL.0b013e3181bc0184.PubMed CentralView ArticlePubMed
- Rauch U, Meyer H, Brakebusch C, Seidenbecher C, Gundelfinger ED, Beier DR, Fassler R: Sequence and chromosomal localization of the mouse brevican gene. Genomics. 1997, 44 (1): 15-21. 10.1006/geno.1997.4853.View ArticlePubMed
- Ruoslahti E: Brain extracellular matrix. Glycobiology. 1996, 6 (5): 489-492. 10.1093/glycob/6.5.489.View ArticlePubMed
- Yamaguchi Y: Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci. 2000, 57 (2): 276-289. 10.1007/PL00000690.View ArticlePubMed
- Gary SC, Zerillo CA, Chiang VL, Gaw JU, Gray G, Hockfield S: cDNA cloning, chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specific proteoglycan regulated during cortical development and in glioma. Gene. 2000, 256 (1–2): 139-147.View ArticlePubMed
- Jaworski DM, Kelly GM, Piepmeier JM, Hockfield S: BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Res. 1996, 56 (10): 2293-2298.PubMed
- Zhang H, Kelly G, Zerillo C, Jaworski DM, Hockfield S: Expression of a cleaved brain-specific extracellular matrix protein mediates glioma cell invasion In vivo. J Neurosci. 1998, 18 (7): 2370-2376.PubMed
- Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT: Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res. 2005, 65 (15): 6726-6733. 10.1158/0008-5472.CAN-05-0585.View ArticlePubMed
- Lu R, Sun M, Feng J, Gao X, Guo L: Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer. BMC Cancer. 2011, 11: 270-10.1186/1471-2407-11-270.PubMed CentralView ArticlePubMed
- Choudhury KR, Yagle KJ, Swanson PE, Krohn KA, Rajendran JG: A Robust Automated Measure of Average Antibody Staining in Immunohistochemistry Images. J Histochem Cytochem. 2010, 58 (2): 95-107. 10.1369/jhc.2009.953554.PubMed CentralView ArticlePubMed
- LU RQ Wu HJ, Guo L: Construction, Expression of HE4 Fusion Protein and its identification. Chin J Lab Diag. 2010, 14: 17-19.
- Nutt CL, Matthews RT, Hockfield S: Glial tumor invasion: a role for the upregulation and cleavage of BEHAB/brevican. Neuroscientist. 2001, 7 (2): 113-122. 10.1177/107385840100700206.View ArticlePubMed
- Hu B, Kong LL, Matthews RT, Viapiano MS: The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility. J Biol Chem. 2008, 283 (36): 24848-24859. 10.1074/jbc.M801433200.PubMed CentralView ArticlePubMed
- Viapiano MS, Hockfield S, Matthews RT: BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to promote glioma invasion. J Neurooncol. 2008, 88 (3): 261-272. 10.1007/s11060-008-9575-8.PubMed CentralView ArticlePubMed
- Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, McNiel EA, Ohlfest JR, Freese AB, Moore PF, et al: Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol. 2007, 85 (2): 133-148. 10.1007/s11060-007-9400-9.PubMed CentralView ArticlePubMed
- Goldbrunner RH, Bernstein JJ, Tonn JC: Cell-extracellular matrix interaction in glioma invasion. Acta Neurochir (Wien). 1999, 141 (3): 295-305. 10.1007/s007010050301. discussion 304–295View Article
- Jaworski DM, Kelly GM, Hockfield S: BEHAB, a new member of the proteoglycan tandem repeat family of hyaluronan-binding proteins that is restricted to the brain. J Cell Biol. 1994, 125 (2): 495-509. 10.1083/jcb.125.2.495.View ArticlePubMed
- Seidenbecher CI, Richter K, Rauch U, Fassler R, Garner CC, Gundelfinger ED: Brevican, a chondroitin sulfate proteoglycan of rat brain, occurs as secreted and cell surface glycosylphosphatidylinositol-anchored isoforms. J Biol Chem. 1995, 270 (45): 27206-27212. 10.1074/jbc.270.45.27206.View ArticlePubMed
- Yamada H, Watanabe K, Shimonaka M, Yamaguchi Y: Molecular cloning of brevican, a novel brain proteoglycan of the aggrecan/versican family. J Biol Chem. 1994, 269 (13): 10119-10126.PubMed
- Viapiano MS, Matthews RT, Hockfield S: A novel membrane-associated glycovariant of BEHAB/brevican is up-regulated during rat brain development and in a rat model of invasive glioma. J Biol Chem. 2003, 278 (35): 33239-33247. 10.1074/jbc.M303480200.View ArticlePubMed
- Wang R, Clark RA, Mosher DF, Ren XD: Fibronectin’s central cell-binding domain supports focal adhesion formation and Rho signal transduction. J Biol Chem. 2005, 280 (31): 28803-28810. 10.1074/jbc.M501421200.View ArticlePubMed
- Yamaguchi Y: Brevican: a major proteoglycan in adult brain. Perspect Dev Neurobiol. 1996, 3 (4): 307-317.PubMed
- Lettau I, Hattermann K, Held-Feindt J, Brauer R, Sedlacek R, Mentlein R: Matrix metalloproteinase-19 is highly expressed in astroglial tumors and promotes invasion of glioma cells. J Neuropathol Exp Neurol. 2010, 69 (3): 215-223. 10.1097/NEN.0b013e3181ce9f67.View ArticlePubMed
- Louis DN: Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006, 1: 97-117. 10.1146/annurev.pathol.1.110304.100043.View ArticlePubMed
- Nutt CL, Zerillo CA, Kelly GM, Hockfield S: Brain enriched hyaluronan binding (BEHAB)/brevican increases aggressiveness of CNS-1 gliomas in Lewis rats. Cancer Res. 2001, 61 (19): 7056-7059.PubMed
- Stanton H, Melrose J, Little CB, Fosang AJ: Proteoglycan degradation by the ADAMTS family of proteinases. Biochim Biophys Acta. 1812, 12: 1616-1629.
- Pilkington GJ: The paradox of neoplastic glial cell invasion of the brain and apparent metastatic failure. Anticancer Res. 1997, 17 (6B): 4103-4105.PubMed
- Subramanian A, Harris A, Piggott K, Shieff C, Bradford R: Metastasis to and from the central nervous system–the 'relatively protected site'. Lancet Oncol. 2002, 3 (8): 498-507. 10.1016/S1470-2045(02)00819-7.View ArticlePubMed
- Cattaruzza S, Perris R: Proteoglycan control of cell movement during would healing and cancer spreading. Matrix Biol. 2005, 24 (6): 400-417. 10.1016/j.matbio.2005.06.005.View ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/607/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.